Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesThe similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients
Journal of Cancer Research & Clinical Oncology, 10/01/09
Kim HR et al. – Pemetrexed has comparable survival benefits in NSCLC patients that show objective response or stable disease
Methods- Retrospectively reviewed medical records
- Patients with histologically proven stage IIIB or IV NSCLC
- Treated with pemetrexed after failure of prior chemotherapy
- Objective response rate for 99 enrolled patients was 13.1% and 22 patients achieved stable disease (SD)—a disease control rate of 35.4%
- Progression-free survival and overall survival (OS) were 1.8 months and 7.6 months
- Patients who achieved SD and pemetrexed-responders showed similar OSs
- Squamous cell carcinoma histology showed no significant OS difference between those that achieved disease control or progression
- Subgroup analysis of OS revealed histology and response to first-line therapy predicted response to pemetrexed
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer
Journal of Clinical Oncology, 11/05/09
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial
Lung Cancer, 11/03/09
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
The Lancet Oncology, 11/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Sponsor
Article Search
Sponsor
Sponsor